Literature DB >> 7615358

Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer.

B Top1, W J Mooi, S G Klaver, L Boerrigter, P Wisman, H R Elbers, S Visser, S Rodenhuis.   

Abstract

A series of 54 resected primary non-small-cell lung carcinomas was analyzed for p53 gene mutations and for p53 protein accumulation and the findings were correlated with clinical parameters. Mutations in exons 5 through 8 of the p53 gene were identified by a denaturing gradient gel electrophoresis (DGGE) assay and cycle sequencing, whereas p53 protein accumulation was detected in paraffin-embedded tissue by immunostaining using 2 different murine monoclonal antibodies (MAbs) (BP53-12 and DO7). A p53 gene mutation and/or p53 protein accumulation was found in 37 of 54 tumors. Mis-sense mutations were closely associated with positive immunostaining, which was intense in 15 out of 17 cases with a mutation. In 10 tumors, obvious p53 accumulation was detected in the absence of mutations in exons 5 through 8. Conversely, only one of 8 p53 non-sense mutations led to detectable p53 accumulation. The most frequent single base changes were G --> T transversions and C --> T transitions. The presence of a p53 alteration was not related to age, tumor size, stage or histology. However, we found a significant inverse correlation between p53 alterations and the presence of a K-ras mutation. This was reflected in the overall postoperative survival data: patients with p53 alterations in their tumors tended to have a better prognosis than those without a p53 alteration; however, this difference was lost when cases with a K-ras mutation were omitted from the analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615358     DOI: 10.1002/ijc.2910640203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Chang-Ping Li; Naoko Iida; Hideaki Oda; Shigetoshi Aiso; Takatoshi Ishikawa
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  P53 expression in stage I squamous cell lung cancer.

Authors:  J Moldvay; J Strausz; M Egerváry; L Agócs; J Bocsi; Z Schaff
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Prognostic role of p53 and Ki-67 immunohistochemical expression in patients with surgically resected lung adenocarcinoma: a retrospective study.

Authors:  Cheol-Hong Kim; Hee Sung Lee; Ju-Hee Park; Jeong-Hee Choi; Seung-Hun Jang; Yong-Bum Park; Myung Goo Lee; In Gyu Hyun; Kun Il Kim; Hyoung Soo Kim; Sung Woo Cho; Won Yong Lee; Eung-Joong Kim; Haeyoung Kim; Jung Weon Shim; Young Hee Choi
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

4.  Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.

Authors:  R J Bold; K R Hess; A S Pearson; A M Grau; F A Sinicrope; M Jennings; D J McConkey; C D Bucana; K R Cleary; P A Hallin; P J Chiao; J L Abbruzzese; D B Evans
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

5.  p53 and angiogenesis in non-small-cell lung cancer.

Authors:  A Giatromanolaki; M I Koukourakis
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 6.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

7.  Regulation of histone modification and chromatin structure by the p53-PADI4 pathway.

Authors:  Chizu Tanikawa; Martha Espinosa; Akari Suzuki; Ken Masuda; Kazuhiko Yamamoto; Eiju Tsuchiya; Koji Ueda; Yataro Daigo; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Commun       Date:  2012-02-14       Impact factor: 14.919

8.  Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer.

Authors:  Nicola Ciancio; Maria Grazia Galasso; Raffaele Campisi; Laura Bivona; Marcello Migliore; Giuseppe U Di Maria
Journal:  Multidiscip Respir Med       Date:  2012-09-14

9.  p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer.

Authors:  F J Vega; P Iniesta; T Caldés; A Sanchez; J A López; C de Juan; E Diaz-Rubio; A Torres; J L Balibrea; M Benito
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.

Authors:  P M Schneider; H W Praeuer; O Stoeltzing; J Boehm; J Manning; R Metzger; U Fink; S Wegerer; A H Hoelscher; J A Roth
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.